GALNT2 Expression Is Reduced in Patients with Type 2 Diabetes: Possible Role of Hyperglycemia

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Marucci, Antonella ^a   di Mauro, Lazzaro ^a   Menzaghi, Claudia ^a   Prudente, Sabrina ^a   Mangiacotti, Davide ^a   Fini, Grazia ^a   Lotti, Giuseppe ^a   Trischitta, Vincenzo ^a,b   Di Paola, Rosa ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLUCOSE; INSULIN; MANNITOL; MESSENGER RNA; PROTEIN GALNT2; TRANSFERASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CELL; CELL STRAIN U937; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GALNT2 GENE; GENE; GENE CONTROL; GENE EXPRESSION; HORMONE ACTION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INSULIN RESISTANCE; LIVER CELL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; SIGNAL TRANSDUCTION;

ADULT; BLOOD GLUCOSE; CELL LINE, TUMOR; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; N-ACETYLGALACTOSAMINYLTRANSFERASES; OBESITY; RNA, MESSENGER;

EID: 84880665189     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070159     Document Type: Article

References (24)

1. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375: 2215-2222.
2. DeFronzo RA, (1988) Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667-687.
3. Taniguchi CM, Emanuelli B, Kahn CR, (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7: 85-96.
4. Marucci A, Cozzolino F, Dimatteo C, Monti M, Pucci P, et al. (2013) Role of GALNT2 in the modulation of ENPP1 expression, and insulin signaling and action. GALNT2: A novel modulator of insulin signaling. Biochim Biophys Acta 1833: 1388-1395.
5. Almon RR, DuBois DC, Lai W, Xue B, Nie J, et al. (2009) Gene expression analysis of hepatic roles in cause and development of diabetes in Goto-Kakizaki rats. Journal of Endocrinology 200: 331-346.
6. Gonzalez Y, Herrera MT, Soldevila G, Garcia-Garcia L, Fabián G, et al. (2012) High glucose concentrations induce TNF-α production through the down-regulation of CD33 in primary human monocytes. BMC Immunol 13.
7. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM, (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95: 2409-2415.
8. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, et al. (1995) The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95: 2111-2119.
9. Hotamisligil GS, (2006) Inflammation and metabolic disorders. Nature 444: 860-867.
10. Rossetti L, Giaccari A, DeFronzo RA, (1990) Glucose toxicity. Diabetes Care 13: 610-630.
11. Ten Hagen KG, Fritz TA, Tabak LA, (2003) All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Glycobiology 13: 1R-16R.
12. Wells L, Vosseller K, Hart GW, (2001) Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 291: 2376-2378.
13. Park SY, Ryu J, Lee W, (2005) O-GlcNAc modification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat primary adipocytes. Experimental Molecular Medicine 37: 220-229.
14. Soesanto YA, Luo B, Jones D, Taylor R, Gabrielsen JS, et al. (2008) Regulation of Akt signaling by O-GlcNAc in euglycemia. Am J Physiol Endocrinol Metab 295: E974-980.
15. Yang X, Ongusaha PP, Miles PD, Havstad JC, Zhang F, et al. (2008) Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature 451: 964-U961.
16. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, et al. (2008) Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nature Genetics 40: 189-197.
17. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, et al. (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nature Genetics 40: 161-169.
18. Holleboom AG, Karlsson H, Lin RS, Beres TM, Sierts JA, et al. (2011) Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man. Cell Metabolism 14: 811-818.
19. Rosenberg S, Elashoff MR, Beineke P, Daniels SE, Wingrove JA, et al. (2010) Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med 153: 425-434.
20. Wingrove JA, Daniels SE, Sehnert AJ, Tingley WG, Elashoff MR, et al. (2008) Correlation of peripheral-blood gene expression with the extent of coronary artery stenosis. Circ Cardiovasc Genet.
21. Yakeu G, Butcher L, Isa S, Webb R, Roberts AW,et al. (2010) Low-intensity exercise enhances expression of markers of alternative activation in circulating leukocytes: roles of PPARγ and Th2 cytokines. Atherosclerosis 212: 668-673.
22. Camargo A, Ruano J, Fernandez JM, Parnell LD, Jimenez A,et al. (2010) Gene expression changes in mononuclear cells in patients with metabolic syndrome after acute intake of phenol-rich virgin olive oil. BMC Genomics 11.
23. ADA (2003) Screening for Type 2 Diabetes. Diabetes Care 26: S21-S24.
24. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N,et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.